BetterLife Pharma BETRF
OTC BETRF
$0.17 -0.01 (-5.56%)
At close: Oct 23, 2026 · 4:00 PM EDT

BetterLife Pharma (BETRF) Return on Equity [ROE] (2015 - 2020)

Updated

BetterLife Pharma's Return on Equity [ROE] was -12951.43% in fiscal Q3 2022 (quarter ended Oct 31, 2021), down 12533.15 percentage points from -418.28% a year earlier.

Analysis

BetterLife Pharma (BETRF) Return on Equity [ROE] (2015 - 2020) Analysis & Trends

For FY2020 (ended Jan 31, 2020), Return on Equity [ROE] at BetterLife Pharma came in at -629.23%, down 21.81 percentage points from FY2019.

  • In earlier fiscal years, Return on Equity [ROE] was -607.42% in FY2019.
  • The fiscal Q3 2022 figure marks the lowest quarterly Return on Equity [ROE] in data going back to fiscal Q1 2019.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 Eli Lilly 1,199.50 Bn 1,168.08 Bn 19.71 Bn 82.09%
2 Johnson & Johnson 635.17 Bn 555.03 Bn 17.30 Bn 19.33%
3 AbbVie 504.69 Bn 477.85 Bn 12.70 Bn -
4 Merck 358.43 Bn 312.86 Bn 12.21 Bn 7.21%
5 Novartis Ag 288.36 Bn 252.75 Bn 11.24 Bn 31.52%
6 Astrazeneca 265.78 Bn 239.54 Bn 12.86 Bn 21.39%
7 Amgen 237.46 Bn 192.86 Bn 7.24 Bn 83.75%
8 Gilead Sciences 193.65 Bn 167.76 Bn 6.22 Bn -18.38%
9 Pfizer 171.05 Bn 118.00 Bn 10.94 Bn 4.97%
10 BetterLife Pharma 25.82 Mn 27.43 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Oct 31, 2020 -421.73%
Jul 31, 2020 -188.44%
Apr 30, 2020 -275.79%
Jul 31, 2019 -98.66%
Apr 30, 2019 -223.37%
Oct 31, 2018 -138.85%
Jul 31, 2018 -84.05%
Apr 30, 2018 -100.99%
Jan 31, 2018 -1,563.64%
Oct 31, 2015 -3,832.43%
Jul 31, 2015 -8,144.90%
API Access

BetterLife Pharma Return on Equity [ROE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=BETRF&period=max&api_key=YOUR_API_KEY